STOCK TITAN

Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags

BOSTON, Aug. 29, 2022 /PRNewswire/ -- – Burns & Levinson is pleased to announce that it represented iVeena Delivery Systems, Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, in a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS). On August 24, iVeena announced that it has licensed its lead asset, IVMED-80, an Orphan Drug Designated eye drop for keratoconus to Glaukos. The agreement grants Glaukos an exclusive global license to develop and commercialize IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with the development and regulatory activities on IVMED-80. In addition, deal terms include the potential for both development and sales milestone payments as well as royalties on sales to iVeena.

The Burns & Levinson intellectual property team was led by Partner Bruce Jobse, who provided advice and counsel during the drafting and negotiations of the license agreement with Glaukos.

iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena is also developing IVMED-85, a first in class, investigational eyedrop formulation for pediatric myopia where it plans to initiate a first in human clinical trial early 2023.

About Burns & Levinson LLP

At Burns & Levinson, we provide high-level, client-centric and results-oriented legal services to our regional, national and international clients. We are a full-service law firm with 125 lawyers in Boston, Providence and London. Our areas of expertise include: business/finance, business litigation, divorce/family law, venture capital/emerging companies, employment, estate planning, government investigations, intellectual property, M&A/private equity, probate/trust litigation, and real estate. We partner with our clients to solve their business and personal legal issues in a collaborative, creative and cost-effective way. For more information, visit Burns & Levinson at www.burnslev.com.

Contact:



Amy Blumenthal

or

Kristen Weller

Blumenthal & Associates


Chief Marketing & Business Development Officer

(617) 879-1511


(617) 345-3555

amyb@blumenthalpr.com


kweller@burnslev.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/burns--levinson-represents-iveena-delivery-systems-inc-in-strategic-licensing-agreement-with-glaukos-corporation-301614032.html

SOURCE Burns & Levinson

Glaukos Corporation

NYSE:GKOS

GKOS Rankings

GKOS Latest News

GKOS Stock Data

5.29B
47.54M
3.86%
105.02%
7.06%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ALISO VIEJO

About GKOS

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde